Clinical Trial: Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft

Brief Summary: Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.

Detailed Summary:
Sponsor: Abgenix

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Abgenix

Dates:
Date Received: May 6, 2002
Date Started: October 1999
Date Completion: June 2003
Last Updated: June 23, 2005
Last Verified: July 2003